title: [Efficacy of low-intensity laser radiation and antibacterial therapy in the treatment of chronic prostatitis in the presence of sexually transmitted infections].
abstract: We studied 94 patients with chronic prostatitis (CP) in combination with urogenital chlamydiasis. The patients were divided into three groups. Group 1 consisted of 32 patients with bacterial prostatitis and sexually transmitted infection (STI). They were treated with fromilid in a dose 500 mg twice a day. Group 2 (n = 27) received also low-intensity laser radiation (LILR) on the prostatic gland. Group 3 patients (n = 35) with abacterial prostatitis were given fromilid (500 mg twice a day). We studied prostatic hemodynamics with color doppler mapping. A specific feature of prostatic vascularisation in CP and STI versus healthy subjects is heterogeneous decline of vessels density in ischemic zones with parallel decrease in these vessels diameter. A peripheral prostatic zone in CP patients with STI was characterized by lower vascularisation than central one. This deteriorates the course of the disease. The results of the study show that adjuvant LILR in CP patients with STI raises efficacy of therapy by 11%. Investigation of prostate vascularisation and hemodynamics of its vessels in CP patients with STI using transrectal ultrasonography and dopplerography provide detailed information about prostatic structure allowing for lesion zones. This facilitates choice of an optimal complex treatment with application of LELR in peripheral inflammation of the prostate.
authors.forename: A I
authors.initials: AI
authors.lastname: Neĭmark
authors.forename: A A
authors.initials: AA
authors.lastname: Khrianin
authors.forename: O N
authors.initials: ON
authors.lastname: Safina
authors.forename: B A
authors.initials: BA
authors.lastname: Neĭmark
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Kondrat'eva
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D002690:Chlamydia Infections / Q000188:drug therapy / Q000382:microbiology / Q000532:radiotherapy; D002908:Chronic Disease; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006801:Humans; D028022:Low-Level Light Therapy; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use; D011467:Prostate / Q000098:blood supply / Q000000981:diagnostic imaging; D011472:Prostatitis / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology / Q000532:radiotherapy; D015231:Sexually Transmitted Diseases, Bacterial / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology / Q000532:radiotherapy; D016896:Treatment Outcome; D018615:Ultrasonography, Doppler, Color; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D014665:Vasodilator Agents; D017291:Clarithromycin; D010431:Pentoxifylline